Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Stock Has Consensus Target Price of $12.67 According to Brokerages

Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) has earned an average rating of “Hold” from the five ratings firms that are currently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating on the company. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $12.67.

Several analysts have recently commented on VRCA shares. Wall Street Zen raised Verrica Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Saturday, September 26th. Lake Street Capital began coverage on Verrica Pharmaceuticals in a research report on Thursday, August 27th. They set a “buy” rating and a $9.00 target price on the stock. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Verrica Pharmaceuticals in a research report on Tuesday.

Hedge Funds Weigh In On Verrica Pharmaceuticals

An institutional investor recently raised its position in Verrica Pharmaceuticals stock. Armistice Capital LLC grew its position in shares of Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) by 75.1% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,118,925 shares of the company’s stock after acquiring an additional 479,732 shares during the quarter. Armistice Capital LLC owned 7.00% of Verrica Pharmaceuticals worth $9,298,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors own 42.45% of the company’s stock.

Verrica Pharmaceuticals Price Performance

VRCA stock opened at $3.78 on Friday. The company has a market capitalization of $64.94 million, a P/E ratio of -2.26 and a beta of 1.60. The company has a debt-to-equity ratio of 0.18, a quick ratio of 1.33 and a current ratio of 1.45. Verrica Pharmaceuticals has a 52-week low of $3.28 and a 52-week high of $9.82. The business has a 50-day simple moving average of $4.73 and a two-hundred day simple moving average of $5.57.

About Verrica Pharmaceuticals

Verrica Pharmaceuticals Inc is a dermatology-focused pharmaceutical company developing and commercializing treatments for skin diseases with limited or inadequate therapeutic options. The company’s work centers on topical therapies designed for use in dermatology practices and other healthcare settings.

Verrica’s lead product, YCANTHE (cantharidin), is a topical solution approved by the U.S. Food and Drug Administration for the treatment of molluscum contagiosum in adults and children two years of age and older.